Key Drivers
- Cash-rich balance sheet
- Zero revenue / net loss
- Sustained cash burn
AIAI Summary
Nuvalent has shifted from a long‑duration R&D bet into a short‑cycle, catalyst‑driven trade—cash into 2029 reduces urgent financing risk, but the Sept‑2026 zidesamtinib PDUFA and H1‑2026 neladalkib NDA compress binary regulatory and commercial execution risk into a 6–12 month window where approvals and early launch metrics will dictate a sharp re‑rating or rapid downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash-rich balance sheet
- •Zero revenue / net loss
- •Sustained cash burn
NUVL is cash-rich and very low‑leverage but generates no revenue, posts large operating losses and negative free cash flow, leaving strong short‑term solvency but high execution and valuation risk.
Price Behavior
Key Price Behavior Insights:
- •Downside momentum
- •Below moving average
- •103–105 resistance
NUVL has weakened over the last month, sliding from $100.50 to $94.77 (~5.7%) and trading ~5.8% below its last-month moving average (~$100.5), signaling short-term bearish momentum with resistance at $103–$105 and immediate support at $94.77.
Price declined ~5.7% from $100.50 on 2026-02-20 to $94.77 on 2026-03-20, highlighting recent pullback
Sentiment & News
Key News Insights:
- •Clinical/regulatory milestones
- •Analyst optimism
- •Institutional sell‑downs
Nuvalent reported Q4/2025 results, reiterated 2026 regulatory and launch milestones for zidesamtinib and neladalkib with a cash runway into 2029, drew upbeat analyst ratings and price‑target upside, but saw sizable institutional sell‑downs.
Clinical and regulatory progress supports upside potential, but large fund selling creates near‑term downside risk and likely keeps the stock volatile
Similar Companies in Healthcare
Other companies in the same sector with AI ratings